Compare HTLD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | ARVN |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.1M | 658.2M |
| IPO Year | 1995 | 2018 |
| Metric | HTLD | ARVN |
|---|---|---|
| Price | $12.45 | $10.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 19 |
| Target Price | $11.50 | ★ $15.05 |
| AVG Volume (30 Days) | 356.8K | ★ 651.5K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,709,000.00 | $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $5.90 |
| 52 Week High | $13.92 | $14.22 |
| Indicator | HTLD | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 49.58 |
| Support Level | $10.67 | $9.02 |
| Resistance Level | N/A | $12.43 |
| Average True Range (ATR) | 0.52 | 0.51 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 54.35 | 61.68 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.